Practice 8

Question 1

Which of the following are SAFETY monitoring parameters of pravastatin therapy? SATA

1. Serum Bilirubin
2. GI upset
3. Myalgias
4. Myopathy

Answer 1

GI upset
Myalgias
Myopathy

Question 2

Which of the following are SAFETY monitoring parameters of simvastatin therapy? SATA

1. Creatine phosphokinase (CPK)
2. Lipids
3. Serum Bilirubin
4. LFTs

Answer 2

Creatine phosphokinase (CPK)
LFTs

Question 3

Which of the following SAFETY monitoring parameters of gemfibrozil therapy? SATA

1. Creatine phosphokinase (CPK)
2. Lipids
3. Serum Bilirubin
4. LFTs

Answer 3

Creatine phosphokinase (CPK)
Serum Bilirubin
LFTs

Question 4

Gemfibrozil is contraindicated in patients who have primary biliary cirrhosis. T/F

Answer 4

True

Question 5

Rosuvastatin is contraindicated in patients who are pregnant. T/F

Answer 5

True

Question 6

Lipitor is lipid-regulating agent that decreases LDL and decreases HDL. T/F

Answer 6

False

Question 7

Lopid is lipid-regulating agent that decreases serum triglycerides and decreases HDL. T/F

Answer 7

False

Question 8

Atorvastatin is a CYP 3A4 inhibitor. T/F

Answer 8

False

Question 9

Gemfibrozil is a 2C19 inhibitor. T/F

Answer 9

True

Question 10

Which of the following medications inhibit CYP 2C9? SATA

1. Lipitor
2. Lopid
3. Crestor
4. Tricor

Answer 10

Lopid

Tricor